Company / SG&A Expense
Arbutus Biopharma Corp SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.9M
FY2025
5-year range
$15.9M / $22.5M
FY2021-FY2025
Trend
-28.1%
vs FY2024
Sector context
#203 of 213
Health Care
What the data says
Among 213 Health Care companies, Arbutus Biopharma Corp is in the top 5% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $16M in FY2025 to $39M in FY2016.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of -2.2%.
Improved from $22M to $16M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -3.8%
- 5-Year CAGR
- -2.2%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 213This company $15.9M Sector average $722.3M
▼
-97.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.2%, indicating a declining trend.
- In FY2025, sg&a expense decreased 28.1% year-over-year.
- Ranks #203 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.9M | -28.1% |
| FY2024 | $22.1M | -1.6% |
| FY2023 | $22.5M | +26.0% |
| FY2022 | $17.8M | +4.1% |
| FY2021 | $17.1M | -3.3% |
| FY2020 | $17.7M | +10.8% |
| FY2019 | $16.0M | -0.8% |
| FY2018 | $16.1M | +0.0% |
| FY2017 | $16.1M | -59.1% |
| FY2016 | $39.4M | +49.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026